Abstract
To evaluate differences in use of sentinel lymph node biopsy (SLNB) by age and race in Medicare recipients with early-stage breast cancer, we examined Surveillance, Epidemiology and End Results—Medicare linked data for women undergoing breast conserving surgery for stage I or II breast cancer, including axillary staging, between January 2000 and December 2002. Multivariable generalized linear modeling with generalized estimating equations was used to identify predictors of receiving SLNB versus standard axillary lymph node dissection as the primary axillary staging modality. Women were significantly less likely to receive SLNB as their primary staging procedure if they were African American (OR 0.65), greater than 80 years of age (OR 0.71 vs. age <70), or dually eligible for Medicare and Medicaid (OR 0.61). Tumor characteristics, including well-differentiated histology and stage I disease, were associated with increased likelihood of SLNB, but estrogen receptor status was not a significant predictor. Women treated at an institution affiliated with an NCI cooperative research group had significantly greater likelihood of receiving SLNB (OR 2.31). Likelihood of receiving SLNB increased for women diagnosed in 2001 and 2002 compared with 2000. Significant disparities exist in receipt of SLNB in the Medicare population, with African Americans, the elderly, and economically disadvantaged patients being less likely to receive this innovative and morbidity-sparing procedure. These findings continue a previously observed pattern of reduced access to state of the art breast cancer care among underserved populations.
Similar content being viewed by others
References
Cabanes PA, Salmon RJ, Vilcoq JR, Durand JC, Fourquet A, Gautier C, Asselain B (1992) Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The breast carcinoma collaborative group of the institut curie. Lancet 339(8804):1245–1248
Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol 6(1):109–116
Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP (2005) American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23(30):7703–7720. doi:10.1200/JCO.2005.08.001
Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657–3663. doi:10.1200/JCO.2006.07.4062
Krag DN, Julian TB, Harlow SP, Weaver DL, Ashikaga T, Bryant J, Single RM, Wolmark N (2004) NSABP-32: Phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol 11(3 Suppl):208S–210S
Krag DN, Anderson SJ, Julian TB, Brown A, Harlow SP, Costantino JP, Ashikaga T, Weaver D, Mamounas EP, Wolmark N (2010) Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients. J Clin Oncol (Meeting Abstracts) 28 (18_suppl):LBA505
Maggard MA, Lane KE, O’Connell JB, Nanyakkara DD, Ko CY (2005) Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer? Ann Surg Oncol 12(1):41–47. doi:10.1007/s10434-004-1168-y
Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E (2008) Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998–2005). J Natl Cancer Inst 100(7):462–474. doi:10.1093/jnci/djn057
Halpern MT, Chen AY, Marlow NS, Ward E (2009) Disparities in receipt of lymph node biopsy among early-stage female breast cancer patients. Ann Surg Oncol 16(3):562–570. doi:10.1245/s10434-008-0205-7
Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW (2008) Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 109(3):545–557. doi:10.1007/s10549-007-9675-8
Freedman RA, He Y, Winer EP, Keating NL (2009) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 27(5):713–719. doi:10.1200/JCO.2008.17.9234
Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362. doi:10.1200/JCO.2005.04.5799
Haggstrom DA, Quale C, Smith-Bindman R (2005) Differences in the quality of breast cancer care among vulnerable populations. Cancer 104(11):2347–2358. doi:10.1002/cncr.21443
Smith GL, Shih YC, Xu Y, Giordano SH, Smith BD, Perkins GH, Tereffe W, Woodward WA, Buchholz TA (2010) Racial disparities in the use of radiotherapy after breast-conserving surgery: a national Medicare study. Cancer 116 (3):734–741. doi:10.1002/cncr.24741
Keating NL, Kouri E, He Y, Weeks JC, Winer EP (2009) Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care 47(7):765–773. doi:10.1097/MLR.0b013e31819e1fe7
Chu KC, Lamar CA, Freeman HP (2003) Racial disparities in breast carcinoma survival rates: seperating factors that affect diagnosis from factors that affect treatment. Cancer 97(11):2853–2860. doi:10.1002/cncr.11411
Curtis E, Quale C, Haggstrom D, Smith-Bindman R (2008) Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112(1):171–180. doi:10.1002/cncr.23131
Bland KI, Scott-Conner CE, Menck H, Winchester DP (1999) Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival. J Am Coll Surg 188(6):586–595 discussion 595–586
Mandelblatt JS, Kerner JF, Hadley J, Hwang YT, Eggert L, Johnson LE, Gold K (2002) Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white. Cancer 95(7):1401–1414. doi:10.1002/cncr.10825
Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A (2008) Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 26(33):5386–5392. doi:10.1200/JCO.2008.17.6891
Owusu C, Lash TL, Silliman RA (2007) Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat 102(2):227–236. doi:10.1007/s10549-006-9321-x
Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293(9):1073–1081. doi:10.1001/jama.293.9.1073
Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25(24):3699–3704. doi:10.1200/JCO.2007.10.9710
Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352 (9132):930–942
Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner M, Lewis D, Cronin K, Chen H, Feuer E, Stinchcomb D, Edwards BK (eds) (2010) SEER Cancer Statistics Review, 1975–2007. National Cancer Institute, Bethesda, MD
Laliberte L, Fennell ML, Papandonatos G (2005) The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer. Med Care 43(5):471–479
Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, Lange JR (2009) Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol 27(11):1857–1863. doi:10.1200/JCO.2008.18.7567
Onega T, Duell EJ, Shi X, Demidenko E, Gottlieb D, Goodman DC (2009) Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients. Med Care Res Rev 66(5):542–560. doi:10.1177/1077558709335536
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 (8 Suppl):IV-3–18. doi:10.1097/01.MLR.0000020942.47004.03
Carpenter WR, Reeder-Hayes K, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, Godley PA (2011) The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care 49 (2):172–179. doi:10.1097/MLR.0b013e3182028ff2
Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M (2003) Trends in breast cancer by race and ethnicity. CA Cancer J Clin 53(6):342–355
Michalski TA, Nattinger AB (1997) The influence of black race and socioeconomic status on the use of breast-conserving surgery for Medicare beneficiaries. Cancer 79(2):314–319. doi:10.1002/(SICI)1097-0142(19970115)79:2<314:AID-CNCR14>3.0.CO;2-3[pii]
Smith GL, Xu Y, Shih YC, Giordano SH, Smith BD, Hunt KK, Strom EA, Perkins GH, Hortobagyi GN, Buchholz TA (2009) Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg 209 (4):425-433 e422. doi:10.1016/j.jamcollsurg.2009.06.363
Edge SB, Gold K, Berg CD, Meropol NJ, Tsangaris TN, Gray L, Petersen BM Jr, Hwang YT, Mandelblatt JS (2002) Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. Cancer 94(10):2534–2541
Koroukian SM, Xu F, Dor A, Cooper GS (2006) Colorectal cancer screening in the elderly population: disparities by dual Medicare-Medicaid enrollment status. Health Serv Res 41(6):2136–2154. doi:10.1111/j.1475-6773.2006.00585.x
Harlow SP, Krag DN (2001) Sentinel lymph node biopsy in breast cancer. Breast Dis 12:43–55
Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, Ku NN, Lyman GH, Berman C, Haddad F, Reintgen DS (1998) Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 227(5):645–651 discussion 651–643
Orr RK, Hoehn JL, Col NF (1999) The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg 134(7):764–767
Olson JA Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2008) Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 26(21):3530–3535. doi:10.1200/JCO.2007.15.5630
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888. doi:10.1016/S1470-2045(07)70278-4
Acknowledgments
This work was funded by NCI Grant 5R01CA124402. The lead author is supported by an NRSA T32 training grant. This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Sect. 103885; NCI contracts N01-PC-35136, N01-PC-35139, and N02-PC-15105; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U55/CCR921930-02. This study was reviewed and approved by University of North Carolina IRB #05-2761 (HPAA-1332).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reeder-Hayes, K.E., Bainbridge, J., Meyer, A.M. et al. Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat 128, 863–871 (2011). https://doi.org/10.1007/s10549-011-1398-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-011-1398-1